CATEGORIES: CMT Update

BioPontis Aliance for Rare Disease: Joint Venture with HNF

by | Dec 9, 2014 | 1 comment

Bio Pontis HNF logo 2 (2)Hereditary Neuropathy Foundation (HNF) is pleased to announce the creation of a joint venture to develop drug candidates for the treatment of Charcot-MarieTooth (CMT) Disease with BioPontis Alliance for Rare Disease.  HNF has supported basic research into the cause of CMT and early translational research to develop critical tools for drug development, with the goal that research would lead quickly to treatment. Progress can become stalled because drug development requires a complex array of more engineering like technical capabilities, capabilities not available to patients and academic researchers alike. Also new attention must be paid to patenting and aligning to the interest/requirements of the drug industry players who will be needed to bring treatments to patients.

To ensure success of potential candidates that are ready to enter clinical trials—not at the earlier stage where potential treatments are first being developed and tested in cells or animal models multiple steps need to be taken—BioPontis Rare Disease Alliance can provide the scientific, business and patenting structure to help bridge to those pharmaceutical companies.

In the Joint Venture, BioPontis Alliance will manage the project’s scientific execution, regulatory strategy, patenting and business partnering. HNF will continue to manage the other important factors that support the drug discovery process, such as basic and early translational research, build and maintain the Global Registry for Inherited Neuropathies and conduct market research and clinical outcome measure research.

Learn more on this topic

Related Blog Posts

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

In Memoriam

The HNF family has lost two great people this summer: Franklin G. Downing Sr. (father of board member Matthew Downing) and George G. Gatta (father of board member Kathleen Zappola).

Targeting PMP22 in CMT1A Patients with Gene Duplication

In previous collaborative work with a group of investigators including Dr Rolf Renne from the University of Florida, Dr. Alex Murashov from East Carolina University and Dr. Lynn Hudson from the NIH-NINDS, we validated a microRNA known as miR29a as a reagent that corrected the expression level of PMP22 in rodent Schwann cells.

Join the conversation

Leave a Comment

1 Comment

  1. Sue Windham

    I have a brother that has been going through this problem for at least 6/7 years. About 2 years ago a Neurologist found out they were treating him for everything but the right thing. She did many test but knew right off he had CMT. He has all the symptoms of the CMT. Started off with his feet and legs. No balance. Could barely walk. Then it hit his arms, hands and muscles. Now he is in a wheelchair. No one knows really what kind of medicine to give him but something to help the pain and anxiety. He has been trying to find a place where they would do a study on him. He is in really bad shape. If you could help me with this please e-mail me and let me know. He cannot use a computer so I am trying to find someone that will send him newsletters about the CMT so he can read it and get more history. I am afraid he is going to end up in a nursing home.

    Thank you so much for the consideration.

    Sue Windham

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news